Humanized antibodies that recognize beta amyloid peptide

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 7790856
APP PUB NO 20070154480A1
SERIAL NO

11520438

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of Aβ in the brain of a patient. Preferred agents include humanized antibodies.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddressTotal Patents
JANSSEN ALZHEIMER IMMUNOTHERAPYMADISON, NJ47

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Schenk, Dale B Burlingame, US 127 4241

Cited Art Landscape

Patent Info (Count) # Cites Year
 
Other [Check patent profile for assignment information] (4)
5227159 Anti-idiotype antibodies reactive with shared idiotopes expressed by B cell lymphomas and autoantibodies 33 1992
2002/0009,445 Human beta-amyloid antibody and use thereof for treatment of alzheimer's disease 99 2001
2002/0197,258 Compositions and methods for preventing protein aggregation in neurodegenerative diseases 88 2002
2004/0247,612 Immunogenic peptide composition for the prevention and treatment of Alzheimer's Disease 29 2004
 
RAMOT AT TEL AVIV UNIVERSITY LTD. (2)
5688651 Prevention of protein aggregation 103 1994
2005/0152,878 Agents and compositions and methods utilizing same useful in diagnosing and/or treating or preventing plaque forming diseases 23 2005
 
BIOCLONES (PTY) LIMITED (1)
6261569 Retro-, inverso- and retro-inverso synthetic peptide analogues 64 1997
 
SYNTEX (U.S.A.) INC. (1)
5208036 N-(.omega., (.omega.-1)-dialkyloxy)- and N-(.omega., (.omega.-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor 146 1990
 
GLAXOSMITHKLINE LLC (3)
5817626 Modulators of beta-amyloid peptide aggregation 78 1995
5854215 Modulators of .beta.-amyloid peptide aggregation 65 1995
5854204 A.beta. peptides that modulate .beta.-amyloid aggregation 111 1996
 
La Jolla Institute for Allergy and Immunology (1)
5910427 Antigen non-specific glycosylation inhibiting factor derivatives 13 1996
 
WISCONSIN ALUMNI RESEARCH FOUNDATION (1)
6022859 Inhibitors of .beta.-amyloid toxicity 34 1997
 
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (2)
6165745 Recombinant production of immunoglobulin-like domains in prokaryotic cells 200 1994
6277375 Immunoglobulin-like domains with increased half-lives 282 1997
 
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (5)
4912206 CDNA clone encoding brain amyloid of alzheimer's disease 40 1987
5472693 Family of anti-carcinoembryonic antigen chimeric antibodies 36 1993
5733548 Immunogenic chimeras comprising nucleic acid sequences encoding endoplasmic reticulum signal sequence peptides and at least one other peptide, and their uses in vaccines and disease treatments 33 1995
2003/0068,316 Anti-ADDL antibodies and uses thereof 81 2002
2003/0166,557 SEMA3B inhibits tumor growth and induces apoptosis in cancer cells 23 2002
 
Eli Lilly and Company (10)
5441870 Methods for monitoring cellular processing of .beta.-amyloid precursor protein 146 1992
5766846 Methods of screening for compounds which inhibit soluble .beta.-amyloid peptide production 143 1993
5612486 Transgenic animals harboring APP allele having swedish mutation 141 1993
6114133 Methods for aiding in the diagnosis of Alzheimer's disease by measuring amyloid-.beta. peptide (x-.gtoreq.41) 104 1994
5624937 Chemical compounds as inhibitors of amyloid beta protein production 84 1995
5593846 Methods for the detection of soluble .beta.-amyloid peptide 218 1995
5605811 Methods and compositions for monitoring cellular processing of beta-amyloid precursor protein 90 1995
5721130 Antibodies and fragments thereof which bind the carboxyl-terminus of an amino-terminal fragment of .beta.APP 106 1995
5837672 Methods and compositions for the detection of soluble .beta.-amyloid peptide 109 1995
6284221 Method for identifying .beta.-amyloid peptide production inhibitors 82 1996
 
UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (1)
2003/0147,882 METHODS FOR AMYLOID REMOVAL USING ANTI-AMYLOID ANTIBODIES 54 1999
 
NEURALAB LIMITED (1)
2005/0123,544 Prevention and treatment of amyloidogenic disease 41 2004
 
SB2, INC. (2)
5624821 Antibodies with altered effector functions 455 1995
5648260 DNA encoding antibodies with altered effector functions 382 1995
 
DMS Pharmaceutical Inc. (1)
5231170 Antibodies to dense microspheres 86 1990
 
BIOSITE INCORPORATED (1)
6057098 Polyvalent display libraries 135 1997
 
RASO, VICTOR (3)
6582945 Immunological control of .beta.-amyloid levels in vivo 66 2000
2002/0136,718 Immunological control of beta-amyloid levels in vivo 63 2001
2005/0147,613 Immunological control of beta-amyloid levels in vivo 38 2005
 
SUNESIS PHARMACEUTICALS, INC. (1)
2007/0021,454 Spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's disease 32 2006
 
ELAN PHARMACEUTICALS, INC. (1)
6610493 Screening compounds for the ability to alter the production of amyloid-.beta. peptide 44 1996
 
CREATIVE BIOMOLECULES, INC. (1)
5258498 Polypeptide linkers for production of biosynthetic proteins 309 1992
 
SCIOS NOVA INC. (3)
5220013 DNA sequence useful for the detection of Alzheimer's disease 77 1989
5187153 Methods of treatment using Alzheimer's amyloid polypeptide derivatives 80 1990
5387742 Transgenic mice displaying the amyloid-forming pathology of alzheimer's disease 195 1991
 
MERCK SHARP & DOHME CORP. (1)
5358708 Stabilization of protein formulations 84 1993
 
SUN HEALTH CORPORATION, INC. (1)
5192753 Anti-rheumatoid arthritic drugs in the treatment of dementia 90 1991
 
PROTHENA BIOSCIENCES LIMITED (1)
6923964 Active immunization of AScr for prion disorders 35 2000
 
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (5)
4666829 Polypeptide marker for Alzheimer's disease and its use for diagnosis 280 1985
5270165 Method of diagnosis of amyloidoses 79 1991
5464823 Mammalian antibiotic peptides 67 1993
5750361 Formation and use of prion protein (PRP) complexes 66 1995
6175057 Transgenic mouse model of alzheimer's disease and cerebral amyloid angiopathy 36 1997
 
Milkhaus Laboratory, Inc. (4)
5753624 Materials and methods for treatment of plaquing disease 89 1996
5798102 Treatment of cardiomyopathy 27 1997
5851996 Materials and methods for treatment of plaquing diseases 94 1998
6294171 Methods for treating disease states comprising administration of low levels of antibodies 78 2001
 
AUTOIMMUNE, INC. (4)
5849298 Treatment of multiple sclerosis by oral administration of bovine myelin 51 1993
5869054 Treatment of multiple sclerosis by oral administration of autoantigens 56 1995
5733547 Treatment of autoimmune arthritis by oral administration of type I or type III collagen 54 1995
5641473 Treatment of autoimmune diseases by aerosol administration of autoantigens 54 1995
 
UNIVERSITY OF IOWA RESEARCH FOUNDATION (1)
6339068 Vectors and methods for immunization or therapeutic protocols 204 1998
 
CELLTECH THERAPEUTICS LIMITED (1)
5677425 Recombinant antibody 120 1994
 
THE UNIVERSITY OF BRITISH COLUMBIA (1)
2006/0234,912 Methods for modulating neuronal responses 17 2006
 
MEMORIAL SLOAN-KETTERING CANCER CENTER (1)
6933368 Increasing antibody affinity by altering glycosylation of immunoglobulin variable region 79 2002
 
WASHINGTON UNIVERSITY (2)
5958883 Animal models of human amyloidoses 79 1995
7195761 Humanized antibodies that sequester abeta peptide 85 2002
 
CELLTECH LIMITED (1)
4816397 Multichain polypeptides or proteins and processes for their production 687 1984
 
FIBROCELL TECHNOLOGIES, INC. (1)
6432710 Compositions for regenerating tissue that has deteriorated, and methods for using such compositions 54 2000
 
New York Blood Center, Inc. (1)
5620844 Assays for detecting hepatitis B virus envelope antigens or antibodies thereto and diagnostic test kits for use in performing the assays 22 1993
 
UNIVERSITY OF KANSAS (1)
5278049 Recombinant molecule encoding human protease nexin 41 1987
 
BRITISH TECHNOLOGY GROUP LIMITED (1)
5096706 Antigen-based treatment for adiposity 27 1986
 
ABBOTT BIOTHERAPEUTICS CORP. (1)
6210671 Humanized antibodies reactive with L-selectin 64 1995
 
Genentech, Inc. (14)
4816567 Recombinant immunoglobin preparations 2160 1983
5245015 Monoclonal antibodies which neutralize HIV-1 through reaction with a conformational epitope in vitro 36 1991
5866129 Method of producing an antibody with a peptide corresponding to membrane-bound IgA 33 1991
6407213 Method for making humanized antibodies 300 1993
5869046 Altered polypeptides with increased half-life 134 1995
6121022 Altered polypeptides with increased half-life 163 1995
6054297 Humanized antibodies and methods for making them 366 1995
5702906 Antibodies to neurotrophic factor-4 (NT-4) 29 1995
6267958 Protein formulation 224 1996
6194551 Polypeptide variants 272 1999
6528624 Polypeptide variants 205 1999
6538124 Polypeptide variants 174 2000
6824780 Anti-tumor antibody compositions and methods of use 85 2000
6639055 Method for making humanized antibodies 123 2000
 
THE OHIO STATE UNIVERSITY (1)
4713366 Antigenic modification of polypeptides 76 1985
 
ABBOTT LABORATORIES (1)
6015662 Reagents for use as calibrators and controls 40 1996
 
IMMUNITOR COMPANY LTD. (1)
2003/0092,145 Viral vaccine composition, process, and methods of use 38 2001
 
AVANT IMMUNOTHERAPEUTICS, INC. (1)
6284533 Plasmid-based vaccine for treating atherosclerosis 48 1998
 
ABBVIE BIOTHERAPEUTICS INC. (1)
5622701 Cross-reacting monoclonal antibodies specific for E- and P-selectin 64 1994
 
THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (1)
5262332 Diagnostic method for Alzheimer's disease: examination of non-neural tissue 67 1989
 
Innogenetics N.V. (1)
2004/0265,919 Method for the prediction, diagnosis and differential diagnosis of Alzheimer's disease 49 2004
 
BAYER PHARMACEUTICALS CORPORATION (1)
5786180 Monoclonal antibody 369.2B specific for .beta. A4 peptide 81 1995
 
EPIMMUNE INC. (1)
5736142 Alteration of immune response using pan DR-binding peptides 83 1994
 
T C U.S.A. INC. (1)
6787129 Castor polyester as gloss agents in anionic systems 18 2003
 
PROTEIN DESIGN LABS, INC. (5)
* 5530101 Humanized immunoglobulins 1125 1990
5585089 Humanized immunoglobulins 1193 1995
5693761 Polynucleotides encoding improved humanized immunoglobulins 528 1995
5693762 Humanized immunoglobulins 940 1995
6180370 Humanized immunoglobulins and methods of making the same 629 1995
 
UCB PHARMA S.A. (2)
2005/0123,534 Humanised antibodies 25 2004
2005/0136,054 Humanised antibodies 23 2004
 
MEDICAL RESEARCH COUNCIL (1)
5225539 Recombinant altered antibodies and methods of making altered antibodies 835 1991
 
CYTRX CORPORATION (1)
5824322 Compositions and methods for growth promotion 57 1996
 
ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (1)
5994083 Process for the preparation of immunogens or diagnostic reagents, and immunogens or diagnostic reagents thereby obtainable 26 1995
 
REGENTS OF THE UNIVERSITY OF MINNESOTA (3)
5837473 Methods of screening for agents affecting the deposition of .beta.-amyloid peptides on amyloid plaques in human tissue 53 1995
5877399 Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease 121 1996
6262335 Transgenic mice expressing APP mutant at amino acids 717, 721 and 722 56 1998
 
CEDARS-SINAI MEDICAL CENTER (1)
5679348 Immunotherapy for recurrent HSV infections 51 1992
 
CELLTECH R&D LIMITED (2)
5859205 Humanised antibodies 461 1994
6632927 Humanized antibodies 251 2001
 
INTELLECT NEUROSCIENCES INC. (1)
2003/0073,655 Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof 87 2002
 
WYETH (2)
2006/0099,206 Methods and compositions for improving recombinant protein production 24 2005
2006/0210,557 Stabilized liquid polypeptide formulations 33 2006
 
NATIONAL RESEARCH COUNCIL OF CANADA (1)
5773007 Vaccine compositions 34 1994
 
NIHON UNIVERSITY (1)
6962984 IgA nephropathy-related DNA 24 2000
 
AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (1)
2006/0182,321 Method and apparatus for extracting third ventricle information 20 2004
 
RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (1)
5589154 Methods for the prevention or treatment of vascular hemorrhaging and Alzheimer's disease 80 1994
 
BTG INTERNATIONAL LIMITED (1)
6548640 Altered antibodies 134 1995
 
WYETH LLC (27)
7189819 Humanized antibodies that recognize beta amyloid peptide 48 2001
7582733 Humanized antibodies that recognize beta amyloid peptide 19 2002
2005/0009,150 Humanized antibodies that recognize beta amyloid peptide 24 2002
7179892 Humanized antibodies that recognize beta amyloid peptide 72 2003
7256273 Humanized antibodies that recognize beta amyloid peptide 59 2003
2004/0171,815 Humanized antibodies that recognize beta amyloid peptide 37 2003
2004/0171,816 Humanized antibodies that recognize beta amyloid peptide 31 2003
2006/0188,512 Active immunization to generate antibodies to solble a-beta 21 2004
2004/0213,800 Active immunization to generate antibodies to soluble A-beta 40 2004
2005/0249,725 Humanized antibodies that recognize beta amyloid peptide 43 2004
2005/0118,651 Humanized antibodies that recognize beta amyloid peptide 47 2004
2007/0134,762 Immunogenic peptide carrier conjugates and methods of producing same 29 2004
2007/0161,088 Beta immunogenic peptide carrier conjugates and methods of producing same 29 2004
2006/0160,161 Methods for assessing antibodies to neurodegenerative disease-associated antigens 39 2005
2006/0153,772 Contextual fear conditioning for predicting immunotherapeutic efficacy 23 2005
2006/0165,682 Humanized antibodies that recognize beta amyloid peptide 35 2005
2006/0198,851 Humanized Abeta antibodies for use in improving cognition 44 2005
2006/0240,486 Immunoprecipitation-based assay for predicting in vivo efficacy of beta-amyloid antibodies 30 2005
2006/0257,396 Abeta antibodies for use in improving cognition 39 2005
2006/0193,850 Anti a beta antibody formulation 48 2006
2006/0280,743 Humanized antibodies that recognize beta amyloid peptide 31 2006
2007/0072,307 Methods of purifying Fc region containing proteins 38 2006
2007/0082,367 Methods of purifying anti a beta antibodies 24 2006
2008/0050,367 Humanized antibodies that recognize beta amyloid peptide 24 2006
2007/0238,154 Humanized antibodies that recognize beta-amyloid peptide 23 2007
2008/0145,373 A-BETA IMMUNOGENIC PEPTIDE CARRIER CONJUGATES AND METHODS OF PRODUCING SAME 32 2007
2009/0142,270 PREVENTION AND TREATMENT OF CEREBRAL AMYLOID ANGIOPATHY 20 2008
 
LILLY AND COMPANY (1)
2004/0241,164 Use of antibodies having high affinity for soluble ab to treat conditions and diseases related to ass 56 2004
 
NOVARTIS AG (1)
2004/0197,324 High concentration antibody and protein formulations 92 2004
 
WYETH HOLDINGS CORPORATION (2)
5723130 Adjuvants for vaccines against respiratory syncytial virus 45 1996
6399314 Methods of detection of amyloidogenic proteins 53 1999
 
Takeda Pharmaceutical Company Limited (2)
5750349 Antibodies to .beta.-amyloids or their derivatives and use thereof 146 1994
5955317 Antibodies to .beta.-amyloids or their derivatives and use thereof 97 1997
 
THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. (2)
5585100 Dual carrier immunogenic construct 77 1995
5955079 Dual carrier immunogenic construct 66 1995
 
BRONSON NUTRITIONALS, LLC (5)
5869093 Treatment of immune diseases by oral administration of autoantigens 65 1994
5645820 Treatment of autoimmune diseases by aerosol administration of autoantigens 62 1995
5571499 Treatment of autoimmune diseases by aerosol administration of autoantigens 80 1995
5571500 Treatment of autoimmune diseases through administration by inhalation of autoantigens 63 1995
5641474 Prevention of autoimmune diseases by aerosol administration of autoantigens 60 1995
 
JANSSEN SCIENCES IRELAND UC (2)
6913745 Passive immunization of Alzheimer's disease 67 2000
2009/0069,544 HUMANIZED ANTIBODIES THAT RECOGNIZE BETA AMYLOID PEPTIDE 15 2007
 
PRAECIS PHARMACEUTICALS INCORPORATED (3)
6303567 Modulators of .beta.-amyloid peptide aggregation comprising D-amino acids 84 1996
5985242 Modulators of .beta.-amyloid peptide aggregation comprising D-amino acids 63 1997
2002/0133,001 Therapeutic agents and methods of use thereof for treating an amyloidogenic disease 46 2001
 
JANSSEN ALZHEIMER IMMUNOTHERAPY (47)
6787523 Prevention and treatment of amyloidogenic disease 79 1998
* 6761888 Passive immunization treatment of Alzheimer's disease 97 2000
6710226 Transgenic mouse assay to determine the effect of A.beta. antibodies and A.beta. Fragments on alzheimer's disease characteristics 64 2000
* 6743427 Prevention and treatment of amyloidogenic disease 122 2000
6750324 Humanized and chimeric N-terminal amyloid beta-antibodies 79 2000
6787138 Prevention and treatment of amyloidogenic disease 69 2000
6787139 Prevention and treatment of amyloidogenic disease 67 2000
6787140 Prevention and treatment of amyloidogenic disease 66 2000
6787143 Prevention and treatment of amyloidogenic disease 57 2000
6787144 Prevention and treatment of amyloidogenic disease 68 2000
* 6787637 N-Terminal amyloid-.beta. antibodies 83 2000
6875434 Methods of treatment of Alzheimer's disease 68 2000
6890535 Pharmaceutical compositions and methods for treatment of amyloid diseases 48 2000
6905686 Active immunization for treatment of alzheimer's disease 59 2000
2004/0081,657 Prevention and treatment of amyloidogenic disease 50 2003
2005/0059,802 Prevention and treatment of amyloidogenic disease 43 2004
2004/0265,308 Prevention and treatment of amyloidogenic disease 50 2004
6808712 Prevention and treatment of amyloidogenic disease 35 2004
6818218 Prevention and treatment of amyloidogenic disease 38 2004
* 6866849 Prevention and treatment of amyloidogenic disease 68 2004
* 6866850 Prevention and treatment of amyloidogenic disease 64 2004
6982084 Prevention and treatment of amyloidogenic disease 41 2004
7014855 Prevention and treatment of amyloidogenic disease 56 2004
2005/0019,328 Prevention and treatment of amyloidogenic disease 45 2004
2005/0059,591 Prevention and treatment of amyloidogenic disease 41 2004
2004/0219,146 Prevention and treatment of amyloidogenic disease 32 2004
6962707 Prevention and treatment of amyloidogenic disease 44 2004
2004/0247,591 Prevention and treatment of amyloidogenic disease 22 2004
2004/0265,301 Prevention and treatment of amyloidogenic disease 27 2004
2005/0158,304 Prevention and treatment of amyloidogenic disease 25 2004
2004/0247,590 Prevention and treatment of amyloidogenic disease 26 2004
2005/0013,815 Prevention and treatment of amyloidogenic disease 40 2004
2005/0019,330 Prevention and treatment of amyloidogenic disease 66 2004
2005/0048,049 Prevention and treatment of amyloidogenic disease 46 2004
2005/0191,292 Prevention and treatment of amyloidogenic disease 25 2004
2005/0249,727 Prevention and treatment of amyloidogenic disease 41 2004
2005/0196,399 Prevention and treatment of amyloidogenic disease 26 2004
6946135 Prevention and treatment of amyloidogenic disease 43 2004
6972127 Prevention and treatment of amyloidogenic disease 63 2004
2005/0163,788 Prevention and treatment of amyloidogenic disease 40 2004
2005/0255,122 Prevention and treatment of amyloidogenic disease 40 2004
2005/0142,132 Prevention and treatment of amyloidogenic disease 44 2005
2005/0191,314 Prevention and treatment of amyloidogenic disease 36 2005
2006/0029,611 Prevention and treatment of amyloidogenic disease 38 2005
2006/0034,858 Prevention and treatment of amyloidogenic disease 38 2005
2007/0154,480 Humanized antibodies that recognize beta amyloid peptide 28 2006
2008/0096,818 PREVENTION AND TREATMENT OF AMYLOIDOGENIC DISEASE 39 2007
 
AMERSHAM PLC (1)
2003/0135,035 Human ZZAP1 protein 24 2002
 
UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (1)
6417178 Amyloid binding nitrogen-linked compounds for the antemortem diagnosis of alzheimer's disease, in vivo imaging and prevention of amyloid deposits 78 1997
 
THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (1)
5858981 Method of inhibiting phagocytosis 43 1996
 
Mindset Biopharmaceuticals (USA) (1)
2002/0086,847 Recombinant antibodies specific for beta-amyloid ends, DNA encoding and methods of use thereof 86 2001
 
BAYER CORPORATION (1)
2002/0160,394 Regulation of transthyretin to treat obesity 61 2002
 
RINAT NEUROSCIENCE CORP. (1)
2006/0057,701 Antibodies directed against amyloid-beta peptide and methods using same 53 2005
 
GENETICS INSTITUTE, LLC (5)
5385887 Formulations for delivery of osteogenic proteins 196 1993
6270757 Formulations for IL-11 27 1994
6372716 Formulations for factor IX 26 1994
5770700 Liquid factor IX formulations 49 1996
5744132 Formulations for IL-12 39 1997
 
Andrulis Pharmaceuticals Corp. (1)
5434170 Method for treating neurocognitive disorders 96 1993
 
XOMA TECHNOLOGY LTD. (2)
5618920 Modular assembly of antibody genes, antibodies prepared thereby and use 184 1994
5576184 Production of chimeric mouse-human antibodies with specificity to human tumor antigens 134 1994
 
University of Saskatchewan (1)
5837268 GnRH-leukotoxin chimeras 31 1996
 
ANTIGENICS INC. (2)
5057540 Saponin adjuvant 221 1990
5583112 Saponin-antigen conjugates and the use thereof 92 1992
 
ZOETIS SERVICES LLC (1)
5989566 Stable vaccine compositions for parenteral administration, a method for their use, and a process for their preparation 54 1996
 
The Scripps Research Institute (3)
4879213 Synthetic polypeptides and antibodies related to Epstein-Barr virus early antigen-diffuse 207 1986
5846533 Antibodies specific for native PrP.sup.Sc 78 1996
6562341 Antibodies specific for native PrPSc 35 2001
 
MASSACHUSETTS INSTITUTE OF TECHNOLOGY (2)
4883666 Controlled drug delivery system for treatment of neural disorders 238 1987
5891991 Amyloid precursor-like protein and uses thereof 36 1996
 
HUNTINGTON POTTER (1)
5780587 Compounds and methods for inhibiting .beta.-protein filament formation and neurotoxicity 80 1995
 
UNIVERSITY OF ROCHESTER (1)
5231000 Antibodies to A4 amyloid peptide 132 1991
 
MCW RESEARCH FOUNDATION, INC. (1)
6057367 Manipulating nitrosative stress to kill pathologic microbes, pathologic helminths and pathologically proliferating cells or to upregulate nitrosative stress defenses 86 1997
 
ALTEON, INC. (1)
5935927 Compositions and methods for stimulating amyloid removal in amyloidogenic diseases using advanced glycosylation endproducts 78 1996
 
MORPHOSYS AG (1)
2005/0169,925 Anti-amyloid beta antibodies and their use 52 2005
 
CITY OF HOPE (2)
5652334 Method for design of substances that enhance memory and improve the quality of life 30 1993
5470951 Peptides for antagonizing the effects of amyloid .beta.protein 44 1993
 
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (1)
6150091 Direct molecular diagnosis of Friedreich ataxia 53 1996
 
PARDRIDGE, WILLIAM (1)
5004697 Cationized antibodies for delivery through the blood-brain barrier 100 1987
 
NEW YORK UNIVERSITY (2)
6713450 Synthetic immunogenic but non-amyloidogenic peptides homologous to amyloid .beta. for induction of an immune response to amyloid .beta. and amyloid deposits 51 2001
2003/0166,558 Synthetic immunogenic but non-deposit-forming polypeptides and peptides homologous to amyloid beta, prion protein, amylin, alpha-synuclein, or polyglutamine repeats for induction of an immune response thereto 56 2002
 
Morphosys Gesellschaft fur Proteinoptimerung mbH (1)
5514548 Method for in vivo selection of ligand-binding proteins 97 1994
 
MILLENNIUM PHARMACEUTICALS, INC. (2)
7147851 Humanized immunoglobulin reactive with .alpha.4.beta.7 integrin 34 1996
6727349 Recombinant anti-CCR2 antibodies and methods of use therefor 28 2000
 
THE GENERAL HOSPITAL CORPORATION (1)
2003/0009,104 In vivo multiphoton diagnostic detection and imaging of a neurodegenerative disease 16 2001
 
THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (2)
5744368 Methods for the detection of soluble amyloid .beta.-protein (.beta.AP) or soluble transthyretin (TTR) 65 1993
7112661 Variable heavy chain and variable light chain regions of antibodies to human platelet glycoprotein Ib alpha 20 1999
 
NEUROCHEM (INTERNATIONAL) LIMITED (2)
6331440 Peptide binding the KLVFF-sequence of amyloid-.beta. 38 1998
2002/0094,335 Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases 80 2001
 
AMGEN INC. (1)
5731284 Method for treating Alzheimer's disease using glial line-derived neurotrophic factor (GDNF) protein product 40 1995
 
SMITHKLINE BEECHAM CORPORATION (1)
6936698 Monoclonal antibodies with reduced immunogenicity 50 2001
 
GLAXOSMITHKLINE BIOLOGICALS SA (1)
5776468 Vaccine compositions containing 3-0 deacylated monophosphoryl lipid A 88 1996
 
PRESIDENT AND FELLOWS OF HARVARD COLLEGE (1)
5601827 Diphtheria toxin vaccines 38 1995
 
UNIVERSITY OF SOUTHERN CALIFORNIA (1)
6218506 Amyloid .beta. protein (globular assembly and uses thereof) 97 1997
* Cited By Examiner

Patent Citation Ranking

Forward Cite Landscape

Patent Info (Count) # Cites Year
 
JANSSEN SCIENCES IRELAND UC (1)
9051363 Humanized antibodies that recognize beta amyloid peptide 0 2007
 
WYETH LLC (7)
8916165 Humanized Aβ antibodies for use in improving cognition 0 2005
8613920 Treatment of amyloidogenic diseases 0 2007
* 2010/0221,187 TREATMENT OF AMYLOIDOGENIC DISEASES 12 2007
* 2008/0279,873 ACTIVE IMMUNIZATION TO GENERATE ANTIBODIES TO SOLUBLE A-BETA 11 2008
8784810 Treatment of amyloidogenic diseases 0 2008
9067981 Hybrid amyloid-beta antibodies 0 2009
8440799 Methods of purifying anti A β antibodies 0 2010
 
JANSSEN ALZHEIMER IMMUNOTHERAPY (3)
8535673 Prevention and treatment of amyloidogenic disease 0 2004
8642044 Prevention and treatment of amyloidogenic disease 0 2007
* 2011/0306,756 Prevention and Treatment of Amyloidogenic Disease 1 2010
* Cited By Examiner

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Mar 7, 2018
11.5 Year Payment $7400.00 $3700.00 $1850.00 Mar 7, 2022
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00